1. Pink Sheet

US FDA Chief Scientist Hinton’s Departure Leaves Vacancy Atop Makena Decision Tree

 
• By Sue Sutter

Jacqueline O’Shaughnessy takes over as acting chief scientist following Denise Hinton’s move to the surgeon general’s office; Hinton previously had been tapped by acting commissioner Janet Woodcock to make a final decision on the accelerated approval status of Covis' preterm birth prevention drug Makena.  

Vacancy sign
FDA chief scientist Denise Hinton's departure means someone else will be responsible for deciding whether Covis' Makena stays on the market or goes. • Source: Alamy

The departure of US Food and Drug Administration chief scientist Denise Hinton means another individual at the agency will be tasked with deciding the fate of Covis Pharma’s preterm birth prevention drug Makena.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

More from Agency Leadership